Cargando…

Unique Genetic Characteristics and Clinical Prognosis of Female Patients with Lung Cancer Harboring RET Fusion Gene

Objectives: Since no report on the genetic characteristics of RET fusions in female patients with lung cancer is available, this study revealed the genetic and prognostic characteristics of female patients with lung cancer harboring RET fusion gene for the first time. Materials and Methods: The mole...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiu, Zhixin, Ye, Bingwei, Wang, Ke, Zhou, Ping, Zhao, Shuang, Li, Weimin, Tian, Panwen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316706/ https://www.ncbi.nlm.nih.gov/pubmed/32587276 http://dx.doi.org/10.1038/s41598-020-66883-0

Ejemplares similares

RET fusion genes in pediatric and adult thyroid carcinomas: cohort characteristics and prognosis
por: Bulanova Pekova, Barbora, et al.
Publicado: (2023)

A case of large-cell neuroendocrine carcinoma harboring rare ALK fusion with initial response to the ALK inhibitor crizotinib and acquired F1174L mutation after resistance
por: Wang, Ye, et al.
Publicado: (2019)

A novel SLC8A1-ALK fusion in lung adenocarcinoma confers sensitivity to alectinib: A case report
por: Deng, Ling, et al.
Publicado: (2022)

Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset
por: Nagasaka, Misako, et al.
Publicado: (2023)

Pralsetinib for the treatment of a RET-positive advanced non-small-cell lung cancer patient harboring both ANK-RET and CCDC6-RET fusions with coronary heart disease: a case report
por: Meng, Yan, et al.
Publicado: (2022)

Durable response to low-dose pralsetinib in a renal insufficient patient with NSCLC harboring concurrent CCDC6-RET, LINCO1264-RET, and SEMA5A-RET fusions: A case report
por: Gu, Linping, et al.
Publicado: (2022)

A RET::GRB2 fusion in pheochromocytoma defies the classic paradigm of RET oncogenic fusions
por: Estrada-Zuniga, Cynthia M., et al.
Publicado: (2022)

Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations
por: Ortiz, Michael V., et al.
Publicado: (2020)

Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma
por: Dias-Santagata, Dora, et al.
Publicado: (2020)

The growth feature and its diagnostic value for benign and malignant pulmonary nodules met in routine clinical practice
por: Zhang, Rui, et al.
Publicado: (2020)

Use of Cabozantinib in a Patient With EGFR-Mutated Non–Small-Cell Lung Cancer Harboring Acquired CCDC6-RET Fusion
por: Chae, Young Kwang, et al.
Publicado: (2019)

Analysis of the clinical characteristics of 77 COVID-19 deaths
por: Wang, Kaige, et al.
Publicado: (2020)

The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis
por: Ke, Jun-yi, et al.
Publicado: (2023)

Non‐canonical Raf‐1/p70S6K signalling in non–small‐cell lung cancer
por: Qiu, Zhixin, et al.
Publicado: (2019)

Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes
por: Lu, Chang, et al.
Publicado: (2022)

Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma
por: Schrenk, Karin G., et al.
Publicado: (2022)

Superior clinical outcomes in patients with non-small cell lung cancer harboring multiple ALK fusions treated with tyrosine kinase inhibitors
por: Wei, Qi, et al.
Publicado: (2023)

Identification and characterization of RET fusions in advanced colorectal cancer
por: Le Rolle, Anne-France, et al.
Publicado: (2015)

Cystic brain metastases and RET fusion in lung cancer
por: Remon, Jordi, et al.
Publicado: (2020)

RET Gene Fusions in Malignancies of the Thyroid and Other Tissues
por: Santoro, Massimo, et al.
Publicado: (2020)

Targeted therapy of RET fusion-positive non-small cell lung cancer
por: Shen, Zixiong, et al.
Publicado: (2022)

The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients
por: Wu, Guowu, et al.
Publicado: (2022)

A Metastatic Pulmonary Sarcomatoid Carcinoma Patient Harboring KIF5B-RET Fusion Responds to First-Line Pralsetinib Treatment: A Case Report
por: Qin, Hao, et al.
Publicado: (2023)

Significant response to pralsetinib in a medullary thyroid cancer harboring double RET variants of unknown significance
por: Hescot, Ségolène, et al.
Publicado: (2022)

Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases
por: Guo, Robin, et al.
Publicado: (2019)

Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion–Positive Breast Cancer
por: Watanabe, Satomi, et al.
Publicado: (2021)

Characteristics of Renal Cell Carcinoma Harboring TPM3-ALK Fusion
por: Woo, Chang Gok, et al.
Publicado: (2020)

RET fusions observed in lung and colorectal cancers are sensitive to ponatinib
por: Gozgit, Joseph M., et al.
Publicado: (2018)

RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC
por: Osta, Badi El, et al.
Publicado: (2020)

Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

RET fusion in advanced non-small-cell lung cancer and response to cabozantinib: A case report
por: Wang, Yucong, et al.
Publicado: (2019)

Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib
por: Zeng, Hao, et al.
Publicado: (2021)

RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation
por: Hayashi, Takuo, et al.
Publicado: (2021)

Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer
por: Yokota, Tomoya
Publicado: (2022)

Efficacy of Combination Chemo-Immunotherapy as a First-Line Treatment for Advanced Non-Small-Cell Lung Cancer Patients With HER2 Alterations: A Case Series
por: Zhao, Shuang, et al.
Publicado: (2021)

Cutaneous Rosai Dorfman disease harboring RET and MAP2K1 mutations, successfully treated with methotrexate
por: Konstantinou, Maria P., et al.
Publicado: (2022)

Highly sensitive droplet digital PCR for detection of RET fusion in papillary thyroid cancer
por: Chen, Mengke, et al.
Publicado: (2023)

RET Fusion Genes in Korean Non-Small Cell Lung Cancer
por: Yoo, Seung Soo, et al.
Publicado: (2013)

Discovery Stories of RET Fusions in Lung Cancer: A Mini-Review
por: Takeuchi, Kengo
Publicado: (2019)

Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lidi8o2f86d8n7o6hi300pqnsm